Mirum Pharmaceuticals Stock (NASDAQ: MIRM)

Dernières nouvelles pour Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

MIRUM PHARMACEUTICALS INC

Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals Inc

OceanPal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) (the "Company"), a global shipping company specializing in the ownership of vessels, today announced that, through a separate wholly-owned subsidiary, it has signed a Memorandum of Agreement to sell the 2004-built dry bulk vessel "Protefs" to a third party, for a sale price of US$7 million before commissions with delivery to the buyer no later than June 17, 2025.
Upon completion of the aforementioned sale,&nbsp;OceanPal Inc.'s fleet will consist of 2 Panamax dry bulk vessels and an MR2 tanker vessel.

News

OceanPal Signs MOA To Sell 2004-Built Dry Bulk Vessel "Protefs" To Third Party For $7M Before Commissions With Delivery To Buyer No Later Than June 17, 2025

Innovex International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) (the "Company" or "Innovex") is pleased to announce that it has completed the acquisition of Citadel Casing Solutions, LLC ("Citadel"), leveraging its unique, energy industrial platform. This investment meets all the criteria of the Company's disciplined M&amp;A framework, including a focus on single-use, highly engineered products that share the Company's "Big Impact, Small Ticket" value proposition.
Founded in 2016 by a team of industry experts, Citadel is a leading provider of differentiated downhole technologies which are designed to improve its customers' economics by driving reduced cycle times through improved operational efficiencies.
The acquisition is financially attractive even prior to expected synergies. The transaction values Citadel at approximately 3.8x LTM Adjusted EBITDA1 and is 8% accretive to Innovex's EPS2. Innovex anticipates realizing approximately $2 million of cost synergies within 3 months and anticipates further synergies longer term as the business is fully integrated.

INVX

Innovex International Completes Acquisition Of Citadel Casing Solutions; Transaction Valued At 3.8x LTM Adjusted EBITDA And Projected To Be 8% Accretive To EPS, With $2M In Cost Synergies Expected Within 3-Months

HC Wainwright &amp; Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) with a Buy rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

SNSE

HC Wainwright & Co. Assumes Sensei Biotherapeutics at Buy, Announces Price Target of $5

MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The grant will support development of MiNK's allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT), in collaboration with the University of Wisconsin.

INKT

MiNK Therapeutics Awarded Grant From NIAID To Support Development Of MiNK's Allo- iNKT Cell Therapy Platform For Prevention And Treatment Of GvHD

One-time Amtagvi Treatment Continues to Show&nbsp; Deep, Durable Responses and Meaningful Survival
One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years
Simultaneous Presentation at ASCO 2025

Biotech

General

IOVA

Iovance Biotherapeutics Publishes Final Analysis Of Phase 2 C-144-01 Clinical Trial Evaluating Individualized T Cell Therapy Amtagvi In Patients With Advanced Melanoma In Journal of Clinical Oncology.

JMP Securities analyst Matthew Condon reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Market Outperform and maintains $95 price target.

Reiteration

ROKU

JMP Securities Reiterates Market Outperform on Roku, Maintains $95 Price Target

RITR

Reitar Logtech Holdings Announces Up To $1.5B BTC Acquisition To Bolster Treasury Reserves And Accelerate Global Logistics Technology Expansion

Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares are trading higher Monday after the company announced long-term lease agreements <a href="https://www.benzinga.com/pressreleases/25/06/g45718843/applied-digital-announces-250mw-ai-data-center-lease-with-coreweave-in-north-dakota">with CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>)</a>.
What Happened: Applied Digital announced Monday that it entered into two lease agreements, spanning approximately 15 years, with AI hyperscaler CoreWeave to deliver 250 megawatts (MW) of critical IT load to host the company&#8217;s AI and high-performance computing infrastructure at its data center site in North Dakota. 
CoreWeave will have the option to add an additional 150 MW of IT load at the data center location. Applied Digital expects to generate approximately $7 billion in revenue from leases over the 15-year contract period.
&#8220;We believe these leases solidify Applied Digital&#8217;s position as an emerging provider of infrastructure critical to the next generation of artificial intelligence and high-performance computing,&#8221; said Wes Cummins, chairman and CEO of Applied Digital.
&#8220;As demand for AI accelerates exponentially, we believe that we are uniquely positioned to deliver substantial returns while supporting the evolving and dynamic needs of these rapidly evolving sectors.&#8221;
Applied Digital expects its first 100 MW data center for CoreWeave to be ready for service in the fourth quarter of 2025. The second 150 MW data center facility is currently under construction and is slated to be ready for service in mid-2026. A third 150 MW data center is in the planning stages and would be ready for service in 2027 if CoreWeave decides to execute its option for the additional site.
Applied Digital&#8217;s site is designed to host 400 MW of critical IT load in total, but the company said it could expand the campus to up to one gigawatt of total power capacity to support additional infrastructure development. 
APLD Price Action: Applied Digital shares were up 22.0% at $8.33 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. CoreWeave shares were up about 4.59% at last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/options/25/05/45695297/looking-at-coreweaves-recent-unusual-options-activity">Looking At CoreWeave&#8217;s Recent Unusual Options Activity</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.

Movers

APLD

CRWV

Applied Digital Stock Surges On AI Data Center Deal With CoreWeave: What You Need To Know

Stifel analyst Nathan Jones maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Hold and raises the price target from $630 to $670.

Stifel Maintains Hold on Parker Hannifin, Raises Price Target to $670

JMP Securities analyst Matthew Carletti initiates coverage on American Integrity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AII#NYSE">AII</a>) with a Outperform rating and announces Price Target of $23.

JMP Securities Initiates Coverage On American Integrity with Outperform Rating, Announces Price Target of $23

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our key level of 587.31. If buyers can step in early, we would like to see an initial move toward 589.71. Sustained strength above this area could encourage further upside movement into 592.00. If momentum remains intact through the session, a continued climb could bring 593.73 into play, with a potential test toward 595.14 as the high target for the bulls.&nbsp;
Should 587.31 fail to hold as support, we will be watching for sellers to challenge 585.75. A breakdown below this level could open the door to further weakness toward 584.68. If selling pressure accelerates, 583.18 will be the next level of interest. In an aggressive downside scenario, the bears may aim for a deeper move toward our low target of 581.97.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently hovering near 517.97. A firm push above 518.65 would give buyers room to drive price action higher toward 519.87. If the bulls can maintain momentum, we will be watching for a potential move up into 521.15, followed by an advance toward 522.57. If strength persists through the day, the high-side target for QQQ sits at 523.91.&nbsp;
On the downside, failure to stay above 517.97 could see sellers take initiative and drive price toward 516.58. Continued weakness could expose the 515.00 level, and if bearish momentum grows, 513.64 will be tested. If sellers dominate the tape, our low target for the session is 511.53.
Apple Inc. (AAPL)
Apple is currently positioned around the 199.51 level. For bulls to gain control, we want to see 200.53 hold as a reliable base. A breakout above this support zone could see the price challenge 202.29. With solid buying pressure, the next upside targets include 203.48 and the high bull target for today at 204.33.&nbsp;
If the 199.51 level breaks down, we'll look for a test of 198.79. Should selling intensify, Apple could trade lower toward 198.22. Additional weakness could invite a test of 197.69, and in the case of a heavy selloff, the low target for today would be 197.00.
Microsoft Corp. (MSFT)
Microsoft is currently auctioning just above 459.18. A strong hold and lift above this level could drive the price toward 460.78. If buyers can sustain control, 462.07 becomes the next area of focus. A continuation of bullish momentum could lift the auction toward 463.27, which is our high target on the day for MSFT.&nbsp;
Should 459.18 fail to act as support, sellers may press toward 457.25. A break below this could bring 455.77 into view. If downside momentum builds, 453.02 will be the next level to monitor, and the low target for the session would be 450.26.
NVIDIA Corporation (NVDA)
NVIDIA is currently near 134.56. Bulls would like to reclaim and hold 135.64 as a solid support area. If buyers can establish control, look for a potential advance toward 136.98. Further strength could drive the auction to 137.94, with the day's high-side target sitting at 138.55.&nbsp;
If 134.56 cannot be defended, a move lower to 133.31 is likely. If this level breaks, 132.19 would be the next key level to watch. Should selling persist, NVIDIA could test 131.42, with the potential to fall toward the low target of 129.53.
Alphabet Inc Class A (GOOGL)
Alphabet is currently auctioning near 169.34. If bulls can push above and hold 171.14 as support, there is a clear path toward 172.28. Continued upside participation could drive the auction higher toward the high target of 174.01.&nbsp;
On the downside, failure to stay above 169.34 could open the door to a move toward 167.04. If sellers remain aggressive, 165.41 will be the next level of interest. A heavy round of selling could pull the price further down toward the low target of 163.79.
Meta Platforms Inc (META)
Meta is currently holding around 642.59. Bulls will need to defend 646.48 as a key support area to initiate a push toward 650.56. If buying momentum builds, price action could extend higher to 655.54, with an eventual test of the high bull target at 658.86.&nbsp;
If 642.59 is breached, sellers may drag the auction lower toward 635.49. Additional downside momentum could test 629.88, and if this area fails to hold, Meta may visit the low target of 622.01.
Tesla Inc. (TSLA)
Tesla is auctioning near 340.97. A bullish move above this level could ignite a rally toward 346.64. Continued buying would likely bring 350.87 into focus, with the potential for an advance toward 356.80. If buyers dominate today's session, the high target for Tesla would be 363.84. If 340.97 cannot hold as a floor, bears could take the auction lower toward 333.93. If downside pressure persists, a test of 327.59 could follow. In the event of strong selling, the low target for Tesla today would be 322.52.
Final Word:&nbsp;
Today's session kicks off June with a series of key economic releases and Fed speakers that could influence volatility. At 9:45 AM ET, we'll see the S&amp;P Global Manufacturing PMI for May. Then at 10:00 AM ET, the market will digest Construction Spending data for April alongside the ISM Manufacturing Index, including components such as Prices Paid, New Orders, and Employment.&nbsp;
Additionally, multiple Fed speakers are scheduled: Logan at 10:15 AM, Goolsbee at 12:45 PM, and Fed Chair Powell delivering remarks at 1:00 PM ET. With this stacked lineup and the fresh start to a new trading month, traders should be prepared for potential swings throughout the session. Stay sharp and manage your risk appropriately. Good luck today!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it's published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Tech

Trading Ideas

Technical Analysis For Trading SPY, Top Tech Stocks Today

Truist Securities analyst John McDonald maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold and raises the price target from $270 to $280.

Truist Securities Maintains Hold on JPMorgan Chase, Raises Price Target to $280

Truist Securities analyst Scot Ciccarelli maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Hold and raises the price target from $81 to $112.

FIVE

Truist Securities Maintains Hold on Five Below, Raises Price Target to $112

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Jordan Alliger downgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Buy to Neutral and maintained the price target of $263. Union Pacific shares closed at $221.66 on Friday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Frank Louthan downgraded the rating for Rackspace Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) from Outperform to Market Perform. Rackspace Technology shares closed at $1.14 on Friday. <a href="https://www.benzinga.com/quote/RXT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Andrew Mok downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and slashed the price target from $84 to $65. Centene shares closed at $56.44 on Friday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>eedham analyst Ami Fadia downgraded the rating for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintained the price target of $130. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Paul Fremont downgraded NorthWestern Energy Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and cut the price target from $57.5 to $56. NorthWestern Energy shares closed at $55.33 on Friday. <a href="https://www.benzinga.com/quote/NWE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying UNP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png" alt="" class="wp-image-935215" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

BPMC

This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

NUBURU's Strategic Growth Potential Enhanced Through Access to Capital and Key Acquisition Targets
NUBURU, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>), a leader in high-power blue laser technology under a pivotal transformation plan, entered into a standby equity purchase agreement (the "Agreement") with YA II PN, Ltd. (the "Investor") under which the company has the option, subject to the conditions set forth therein, to sell up to $100 million in shares. This facility provides NUBURU with the financial flexibility to execute controlled stock sales until May 30, 2028.
The Agreement, executed on May 30, 2025, allows NUBURU to sell shares valued up to $100 million at its discretion, which will be based on market conditions and the company's evolving needs. Under the terms of the Agreement, NUBURU maintains full authority over the timing and quantity of any share sales, ensuring strategic control over its funding operations and empowering NUBURU to dictate the pace and volume of equity sold, aligning sales strategies with operational goals. Certain conditions, including an effective registration statement, must be satisfied before the company may make any sales under the Agreement.
The purchase price for the equity sales under the Agreement will be 97% of the lowest daily volume-weighted average price (VWAP) of the common shares over the three trading day period following the company's submission of a sale notice to the Investor.
The proceeds from any stock sales under this agreement are intended for general corporate purposes, including working capital and growth initiatives, consistent with NUBURU's strategic commitments outlined in its transformation plan. In line with these growth ambitions, the Company recently disclosed its plan to acquire a controlling interest in Tekne S.p.A. ("TEKNE") <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fen.tekne.it&amp;esheet=54263377&amp;newsitemid=20250602013772&amp;lan=en-US&amp;anchor=https%3A%2F%2Fen.tekne.it&amp;index=1&amp;md5=c92ecafe09893f6a05f162b1582f834c">https://en.tekne.it</a>, pending regulatory and stockholder approval. TEKNE is known for its unique capability to unify advanced electronics and special-purpose vehicle engineering under one roof to deliver fully integrated, mission ready, high-performance systems. Its core strength lies in the depth expertise of its engineering department, with roots in the division it acquired from Thalesin 2016. TEKNE conducts operations globally and has established commercial and support operations in the U.S., including its strategic partnership in 2024 with U.S.-based Flyer Defense, a leading provider of tactical ground mobility solutions. Together, TEKNE and Flyer Defense have announced plans to produce the Flyer 72-Heavy Duty vehicle, designed for rapid deployment across diverse military operations. This collaboration aims to enhance the capabilities of the Italian armed forces and its NATO allies, including U.S. armed forces, fostering an environment of interoperability and readiness. TEKNE's board of directors aims to further enhance its governance and strategic support by appointing senior advisers with a background in serving the US armed forces. Leveraging this expertise, TEKNE intends to expand its presence in the U.S. market, including plans to establish a technology laboratory focused on addressing specific U.S. defense-tech needs.

BURU

NUBURU Announces $100M Equity Facility To Enhance Financial Flexibility Through 2028

JMP Securities analyst Matthew Carletti initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Market Outperform rating and announces Price Target of $45.

JMP Securities Initiates Coverage On Aspen Insurance Hldgs with Market Outperform Rating, Announces Price Target of $45

Truist Securities analyst Scot Ciccarelli maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Buy and raises the price target from $89 to $100.

DLTR

Truist Securities Maintains Buy on Dollar Tree, Raises Price Target to $100

BWS Financial analyst Hamed Khorsand maintains Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) with a Buy and maintains $31.5 price target.

BWS Financial Maintains Buy on Movado Group, Maintains $31.5 Price Target

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $450 to $400.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $400

Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) will release its first-quarter earnings results before the <a href="https://www.benzinga.com/quote/sig/earnings">opening bell on Tuesday, June 3</a>.
Analysts expect the Hamilton, Bermuda-based company to report quarterly earnings at $1.04 per share, down from $1.11 per share in the year-ago period. Signet Jewelers projects to report quarterly revenue at $1.52 billion, compared to $1.51 billion a year earlier, according to data from Benzinga Pro.
On March 19, the company reported a fourth-quarter sales decline of 5.8% year-on-year to $2.35 billion, beating the analyst consensus estimate of $2.33 billion.
Signet Jewelers shares fell 0.5% to close at $66.57 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SIG/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating with a price target of $62 on May 28, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and raised the price target from $60 to $70 on May 14, 2025. This analyst has an accuracy rate of 72%.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained a Neutral rating and cut the price target from $95 to $65 on Jan. 15, 2025. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying SIG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02043317/image-1-1024x584.png" alt="" class="wp-image-934761" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02043317/image-1-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02043317/image-1-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02043317/image-1-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02043317/image-1.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Comments

Mirum Pharmaceuticals

Actualités

Dernières nouvelles pour Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL